The researchers found that an ECOG
performance status of ≥2 was linked to lower patient satisfaction and perceived effectiveness of their treatment.
Patients eligible for treatment will be those (1) for whom a cell line has been established, (2) who have undergone leukapheresis from which sufficient monocytes were obtained, (3) have an ECOG
performance grade of 0 or 1 (Karnofsky score of 70-100%), (4) who have either never received treatment for metastatic melanoma or were previously treated with enzymatic inhibitors of the BRAF/MEK pathway because of BRAF600E/K mutations and (5) are about to initiate anti-PD1 monotherapy.
In terms of limitations, the study only included cancer patients who received less than four points on the ECOG
scale and were treated at a single private facility.
AAP: abiraterone acetate plus prednisone; ADT: androgen-deprivation therapy; AR: androgen receptor; CI: confidence interval; ECOG
PS: Eastern Cooperative Oncology Group performance status; HR: hazard ratio; ITT: intention to treat population; LHRHA: luteinizing hormone releasing hormone antagonist; Ml: metastatic; mCSPC: metastatic castration-sensitive prostate cancer; NR: not reported; NYR: not yet reached; OS: overall survival; PCa: prostate cancer; PFS: progression-free survival; PSA: prostate-specific antigen; rPFS, radiographic progression-free survival; RP: radical prostatectomy; RT: radiation therapy; SOC: standard of care.
The secondary outcomes were defined as hearing changes, the number of sick days by month, ECoG
recording, and functional level.
performance status was stage 1 in 11 (13.75%) patients, was stage 2 in 37 (46.25%) patients, was stage 3 in 26 (32.5%) patients and was stage 4 (7.5%) in 6 patients.
30 (69.8%) patients had ECOG
performance score 1 and 13 (30.2%) patients had ECOG
Chemo-naive patients, aged 18 to 80 years, with histopathologically proven urothelial carcinoma of urinary bladder, clinicalstage II or III, having creatinine clearance <40 ml/min, with Eastern Cooperative Oncology Group - Performance Status (ECOG
PS) a$?2 and normal peripheral blood counts and liver functions were enrolled in the study.
Eligible patients were [greater than or equal to]20 years old, with Eastern Cooperative Oncology Group (ECOG
) performance status 0 or 1, histologically confirmed invasive breast cancer with clinical stage T1c-3, N0/M0 or T1-3, N1/M0, and had received no treatment for their current breast cancer.
Electronic medical records were subsequently reviewed to investigate patient demographics as well as laboratory and clinical characteristics at presentation, including white blood cell (WBC) count; hemoglobin; platelets; lactate dehydrogenase (LDH); Eastern Cooperative Oncology Group (ECOG
) performance status, which assesses the functional status of the patient; and the MIPI score.
After adjusting for lactate dehydrogenase, ECOG
(Eastern Cooperative Oncology Group) status, disease stage, and treatment, hazard ratios for overall survival were 1.75 (95% confidence interval, 1.352.28) for detectable versus undetectable circulating tumor DNA (ctDNA) and 1.24 (95% CI, 1.00-1.53) for high versus low circulating hepatocyte growth factor (cHGF), reported William Lu, PhD, of Genentech in South San Francisco, with his associates.
Oncesinde metastatik mide adenokarsinomu icin kemoterapi alan, ECOG
(Eastern Cooperative Oncology Group) performans durumu > 3 olan, ikinci bir kanseri olan, tani esnasinda merkezi sinir sistemi metastazi olan, DCF (sisplatin 60 mg/[m.sup.2] 1.gun, intravenoz infuzyon - dosetaksel 60 mg/[m.sup.2], 1.gun, intravenoz infuzyon, 5-fluorourasil 600 mg/m2, 1-4 gun 21 gunde bir dongu) kemoterapisi uygulanabilmesi icin yeterli bobrek (serum kreatinin duzeyi < 1,5 mg/dL), karaciger (ALT < normalin ust sinir x 2) ve hematolojik (lokosit sayisi [greater than or equal to] 3500 ve mutlak notrofil sayisi [greater than or equal to] 1500) kapasitesi olmayan hastalar ve gebeler calismaya dahil edilmedi.